Tokio Marine Asset Management Co. Ltd. Acquires 1,221 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Tokio Marine Asset Management Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,326 shares of the biotechnology company’s stock after purchasing an additional 1,221 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in BioMarin Pharmaceutical were worth $1,467,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its holdings in BioMarin Pharmaceutical by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,784 shares of the biotechnology company’s stock valued at $2,681,000 after purchasing an additional 3,793 shares during the period. Mediolanum International Funds Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at approximately $1,237,000. Swedbank AB raised its position in shares of BioMarin Pharmaceutical by 11.2% in the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company’s stock valued at $28,403,000 after buying an additional 43,593 shares in the last quarter. R Squared Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at approximately $121,000. Finally, Pacer Advisors Inc. raised its position in shares of BioMarin Pharmaceutical by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 37,423 shares of the biotechnology company’s stock valued at $2,460,000 after buying an additional 1,938 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the transaction, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BMRN has been the subject of several analyst reports. Evercore ISI dropped their target price on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. William Blair cut shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. lowered their price objective on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a research report on Wednesday, October 30th. Canaccord Genuity Group lowered their price objective on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Stock Down 1.5 %

Shares of NASDAQ BMRN opened at $62.44 on Tuesday. The firm has a market cap of $11.90 billion, a PE ratio of 37.39, a P/E/G ratio of 0.55 and a beta of 0.29. BioMarin Pharmaceutical Inc. has a 12-month low of $60.63 and a 12-month high of $94.85. The company’s fifty day simple moving average is $65.15 and its 200 day simple moving average is $72.82. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.